2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148668
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC50=2.2 μM).
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan
  • HY-153795
    Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan
    		99.09%
    Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan is a drug-linker conjugate for ADC. Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan consists of Exatecan (HY-13631) and a linker. Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan can be used for synthesis of ADCs and for cancer research.
    Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan
  • HY-153032
    Val-Ala-PAB-MMAE
    		98.89%
    Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. MMAE is an effective inhibitor of tubulin.
    Val-Ala-PAB-MMAE
  • HY-135660
    MMAE-SMCC
    		99.56%
    MMAE-SMCC is a agent-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE (HY-15162) and a linker SMCC to make antibody agent conjugate.
    MMAE-SMCC
  • HY-126681
    SC-VC-PAB-MMAE
    SC-VC-PAB-MMAE is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.
    SC-VC-PAB-MMAE
  • HY-132250
    MCC-DM1
    		99.52%
    MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues.
    MCC-DM1
  • HY-154915
    MC-EVCit-PAB-MMAE
    		99.04%
    MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162).
    MC-EVCit-PAB-MMAE
  • HY-156755
    Propargyl-PEG4-GGFG-DXd
    		99.99%
    Propargyl-PEG4-GGFG-DXd is a drug-linker conjugate for ADC. Propargyl-PEG4-GGFG-DXd contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D).
    Propargyl-PEG4-GGFG-DXd
  • HY-141155
    endo-BCN-PEG4-Val-Cit-PAB-MMAE
    		99.95%
    endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable ADC linker conjugated with drug containing 4-unit PEG, which can be used for synthesizing antibody-drug conjugates (ADCs). endo-BCN-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    endo-BCN-PEG4-Val-Cit-PAB-MMAE
  • HY-136288
    Azide-PEG4-VC-PAB-Doxorubicin
    		98.47%
    Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC). Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Azide-PEG4-VC-PAB-Doxorubicin
  • HY-16261B
    MC-DOXHZN hydrochloride
    		98.04%
    MC-DOXHZN ((E/Z)-Aldoxorubicin) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.
    MC-DOXHZN hydrochloride
  • HY-153013
    SN38-COOH
    		98.85%
    SN38-COOH is used for the synthesis of antibody-drug conjugates (ADCs). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis.
    SN38-COOH
  • HY-147363
    DIBAC-GGFG-NH2CH2-Dxd
    		99.69%
    DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates. Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DIBAC-GGFG-NH2CH2-Dxd
  • HY-148426
    OSu-PEG4-VC-PAB-MMAE
    		98.91%
    OSu-PEG4-VC-PAB-MMAE involves in GDP-FAmP4MMAE (Monomethylauristatin E) synthesis, which is for GDP label via site-specific conjugation.
    OSu-PEG4-VC-PAB-MMAE
  • HY-148875
    Py-MAA-Val-Cit-PAB-MMAE
    		99.78%
    Py-MAA-Val-Cit-PAB-MMAE is a drug-Linker conjugates for ADC, which is composed of MMAE (HY-15162) and Py-MAA-Val-Cit-PAB linked. Py-MAA-Val-Cit-PAB-MMAE can be used to synthesize Zapadcine-3a, which targeting TRAILR2. Zapadcine-3a has broad-spectrum anti-tumor activity, and can specifically kill TRAILR2-positive tumors.
    Py-MAA-Val-Cit-PAB-MMAE
  • HY-164792
    DBCO-PEG3-VC-Exatecan
    DBCO-PEG3-VC-Exatecan (compound 25) is a Drug-Linker Conjugate for ADC. DBCO-PEG3-VC-Exatecan contains the ADC linker (DBCO-PEG3-VC) and a DNA topoisomerase I inhibitor Exatecan (HY-13631).
    DBCO-PEG3-VC-Exatecan
  • HY-147095
    Val-Ala-PABC-Exatecan
    		99.90%
    Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC，consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor，HY-13631). Val-Ala-PABC-Exatecan can be used for ADC molecues synthesis，such as Mal-PEGn-amide-va-Exatecan.
    Val-Ala-PABC-Exatecan
  • HY-19812
    Acetylene-linker-Val-Cit-PABC-MMAE
    Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a agent-linker conjugate for ADC. Acetylene-linker-Val-Cit-PABC-MMAE is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Acetylene-linker-Val-Cit-PABC-MMAE
  • HY-141833
    Bi-Mc-VC-PAB-MMAE
    		99.78%
    Bi-Mc-VC-PAB-MMAE consists ADCs linker (Bi-Mc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE, HY-15162). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC.
    Bi-Mc-VC-PAB-MMAE
  • HY-126685
    Mal-PEG4-VA-PBD
    Mal-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via Mal-PEG4-VA.
    Mal-PEG4-VA-PBD
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.